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did not have LI at 1 month post- AlloHSCT. On multivariate
analysis, only bloodstream bacterial infections (P ¼ .0059)
and invasive fungal infections (P ¼ .0020) were signiﬁcant
risk factors for developing LI at 1 month. On multivariate
analysis for risk factors for TRM, only LI at 1 month post-
AlloHSCT (P ¼ .0001), primary graft failure (P ¼ .0096) and
bloodstream bacterial infections (P ¼ .0328) were signiﬁcant.
However, LI prior to AlloHSCT conditioning was not associ-
ated with higher TRM.
Conclusions: TRM among pediatric patients with LI at 1
month post-AlloHSCT is extremely high, with infections
being the primary risk factor for LI.Table 1
Relapse rates, by MRD286
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Extracorporeal photopheresis (ECP) is an established
second line treatment option for graft versus host disease
post hematopoietic progenitor cell transplant. At our center
the Therakos Cellex has replaced the UVAR-XTS machine for
ECP since 2009. We reviewed the records of 385 procedures
using the Therakos Cellex. Nine patients underwent ECP for
GVHD. The median age was 13.5 years (range 3.7 to 24) and
weight was 49.2 kg (range 18.5-86.3). ECP was initiated at
a median of 7.5 months (range 0.3-34.8) from the onset of
GVHD. The mean duration per procedure was 106 minutes
(range 60-205). Fifteen (3.9%) procedures were cancelled and
10 (2.6%) were delayed with central venous line (CVL) issues
being the most frequent problem. Instillation of prophylactic
tissue plasminogen activator (tPA) in the CVL lumens prior to
a procedure was instituted 6 months before the end of study
period, to reduce the incidence of CVL related occlusions and
sluggish returns. With change in practice, fewer CVL related
occlusions were observed (4.7% vs. 2.3%). There was one
episode of CVL-associated thrombosis and one episode of
delayed bleeding (mild and spontaneously resolved). There
were four episodes of viral reactivation, 4 CVL-associated
infections (1142 catheter days) and 1 episode of systemic
inﬂammatory response syndrome. No patient experienced
hypotension that requiredmedical intervention. Although no
additional adverse events were noted, there was consider-
able blood exposure in the smallest patients because of the
need for machine blood prime. The Therakos Cellex appears
to be safe and well-tolerated in 385 procedures performed in
our institution. This is the ﬁrst report regarding the safety
and tolerability of this device for ECP in children and young





No 20 7 35%
Yes 11 7 64%
Acute myelogenous
leukemia
No 15 3 20%
Yes 11 4 36%
Mixed phenotype
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Background: Relapse is the primary cause of treatment
failure post alloHCT. We sought to identify risk factors that
predict relapse of hematologic malignancies after allogeneic
hematopoietic cell transplantation (alloHCT) to identify
those at highest risk of relapse who may beneﬁt from novel
therapies.
Design: This was a single institution, retrospective cohort
study of children with acute lymphoblastic leukemia (ALL),
acute myelogenous leukemia (AML), mixed phenotypic acute
leukemia (MPAL) and myelodysplastic syndrome (MDS) who
had undergone alloHCT between 1/1/2003 and 12/31/2010.
Relapse was deﬁned as any evidence of increasing disease
post-alloHCT, including minimal residual disease (MRD).
Relapse-free survival (RFS) was estimated by the Kaplan-
Meier method and the log-rank test used to assess univariate
associations with various characteristics. A Cox proportional
hazards model was used to identify factors jointly associated
with RFS.
Results: Of 70 children who underwent a myeloablative HCT
for MDS or acute leukemia in complete remission at the time
of HCT, 24 (34%) relapsed at a median of 214 days (range 1
month- 57 months) post-HCT. Relapse rates by disease were
14/31 (45%) for ALL; 7/26 (27%) for AML; 3/9 (33%) for MPAL;
0/4 (0%) for MDS. Univariate analysis demonstrated that
black race, central nervous system (CNS) disease at diagnosis
(Figure 1), greater number of regimens given to induce
remission and MRD pre-HCT were associated with higher
relapse probability. In a Cox model, either two or more
regimens needed to achieve remission or the presence of
both pre-HCT MRD and CNS disease were approximately
equally predictive of increased relapse risk. In patients with
ALL, CNS disease was more highly associated with relapse
risk than MRD. For those who were MRD negative, based
on 19 total patients, the presence of CNS disease at
diagnosis (n¼2) was signiﬁcantly associated with higher
relapse risk (P < .0001).
Conclusion: We identiﬁed CNS involvement at diagnosis as
a novel risk factor associated with relapse risk after alloHCT.
This may be due to inherent biologic differences leading to
higher risk disease, or as a sanctuary site, the CNSmay be less
amenable to an allogeneic effect. These patients may beneﬁt
from earlier or more intensive CNS-directed therapy to
reduce relapse risk. Validation of these risk factors in a larger
population and development of a prognostic score to identify
those at highest risk of relapse in addition to a biology study
to evaluate for MRD in the CNS using ﬂow cytometery is
planned. The goal is for prospective use of this prognostic
tool in the development of relapse prevention trials.
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Introduction: Newborn Screening (NBS) for Severe
Combined Immunodeﬁciency (SCID) began in 2008 in the
state of Wisconsin. It is predicted that early detection
through NBS will improve hematopoietic cell transplant
(HCT) outcomes for infants diagnosed with SCID. Two
patients were diagnosed by NBS with absent T cell receptor
excision circles (TRECs). The results of their workup and HCT
outcomes are reported here. These two patients emphasize
the dilemmas faced since implementation of NBS SCID
screening.
Results: Both patients were non-dysmorphic, demonstrated
thymic tissue on ultrasound, were negative for maternal
engraftment, and lacked a genetic diagnosis despite exten-
sive expedited gene sequencing. Patient 1 had a classical
SCID phenotype with T-B-NK+ immunophenotype and
markedly diminished PHA response. There was concern for
a radiosensitive form of SCID in patient 1; therefore, a skin
ﬁbroblast line was established. Just prior to transplantation
mild, radiosensitivity was reported. Patient 2 had a non-
classical SCID phenotype with TloB+NK+ immunophenotype
and normal PHA response at birth. Patient 2 was placed in
protective isolation and prophylaxis while extensive workup
ensued. During this observation period, TRECs remained
undetectable and immunophenotype did not change.
Further T cell analysis demonstrated normal spectratyping,
but diminished T cell response to CD3 crosslinking. B cell
functional analysis revealed normal isoagglutinnin titers and
a positive response to killed rabies vaccination. The decision
to transplant was made based on abnormal anti-CD3
response, persistently undetectable TRECs, asymptomatic
low-level CMV detection, and excellent donor source. At 2.5
months of age, patient 1 underwent a 9/10 UCB HCT, and at
16.5 months of age, patient 2 underwent an MSD HCT. Both
patients received RIC conditioning with Busulfan (CSS 400-
600 ng/ml), Fludarabine, and ATG, and CSA with MMF or
MTX for GVHD prophylaxis. Engraftment occurred on days
+28 (patient 1) and +24 (patient 2). Neither patient devel-
oped GVHD. Post-HCT complications for patient 1 includedbacteremia and for patient 2 included transaminitis, mild
SOS, and CMV reactivation. Both patients are alive andwell at
830 (patient 1) and 53 days (patient 2) post-HCT.
Conclusions: These two patients illustrate the successes and
challenges of NBS for SCID. For example, rapid radiosensitive
assays are needed along with widely available and stan-
dardized protocols for assessing B cell function in infants.
Large, multicenter, prospective trials are needed to deﬁne
criteria for HCT, optimal conditioning regimen, and age for
HCT in clinically well newborns lacking a genetic diagnosis.289
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Delayed immune reconstitution after allogeneic trans-
plant for pediatric acute leukemia has been implicated by
some studies as a risk for leukemic relapse. However, results
regarding the speciﬁc laboratory parameters of interest have
been conﬂicting. We initiated a retrospective review of 97
pediatric patients who underwent allogeneic stem cell
transplantation for ALL, AML or JMML between the years of
2000 and 2010. We collected available clinical outcomes data
which included lymphocyte subset (CD3, CD4, CD8, CD19,
CD16/56) recovery at 90 and 180 days, proliferative response
of CD3 T cells to phytohemagglutinin (PHA) at 90 and 180
days, and donor CD3 chimerism at 30 days post-transplant.
Median cutoffs associated with immune reconstitution that
were used for data analysis included a CD4 count >200, CD8
count >200, and PHA >30% of lower limit of normal control.
Full donor CD3 chimerismwas deﬁned as no evidence of host
DNA down to a sensitivity of 1%. Data for immunophenotype
was available for 71 patients; CD3 chimerism was available
for 50 patients, and PHA responses were available for 47
patients.
No signiﬁcant difference in CD4 or CD8 Tcell recoverywas
detected between relapse and non-relapse patients.
However, a higher rate of relapse was observed in patients
with a PHA response <30% within the ﬁrst 180 days (4/7, 5-
year RFS 42.8%), compared to those with PHA >30% (5/40, 5-
year RFS 84.8%, P ¼ .02). In the subset of patients for whom
both PHA and chimerism datawere available, a higher rate of
relapse was observed in patients with either mixed CD3
chimerism or poor PHA response (8/27), compared to those
who recovered both full donor CD3 chimerism and CD3 PHA
response >30% (0/7, P ¼ .1).
Historically, tailoring of immunotherapy post-transplant
has focused on the treatment of graft-versus-host disease.
With the availability of clinical tools to better predict
leukemic relapse post-transplant, further intervention (such
as withdrawal of immunosuppression and/or DLI) may be
implemented safely and effectively for those who require it.
This preliminary data indicates that PHA response is a clini-
cally accessible indicator of immune reconstitution that may
be an important variable to consider when predicting
a patient's risk for relapse. Further study is needed to
determine the degree to which PHA response might affect
speciﬁc groups of patients.
